First Ascent Biomedical, a pioneer in personalized cancer treatment, announced a $6 million investment from Vidal Duart Enterprises, Inc., with an additional co-investment from Techstars. The funding will accelerate First Ascent Biomedical's mission to transform medical oncology with highly individualized, prospective treatment planning technologies that improve patient survival.